(NASDAQ:AMRS) shares saw heavy trading volume with 443K shares changing hands in the last trading session. Trading volume was up 85.91% over the stocks average daily volume.
Traders are more bullish on shares of Amyris Inc lately if you put credence in the fall in short interest. The firm realized a fall in short interest between September 29, 2017 and October 13, 2017 of -2.83%. Short interest decreased 98,250 over that period. Days to cover increased from 10.0 to 19.0 and the percentage of shorted shares was 0.09% on October 13.
The following firms have recently changed their position in AMRS. As of quarter end Goldman Sachs Group Inc had bought 44,981 shares growing its stake by 270.9%. The value of the investment in AMRS increased from $12,000 to $33,000 a change of 175.0% quarter over quarter. As of the end of the quarter Morgan Stanley had disposed of a total of 44,731 shares trimming its position 98.2%. The value of the total investment in Amyris Inc went from $33,000 to $0 a change of $33,000 for the reporting period.
As of quarter end Nelson Roberts Investment Advisors, LLC had disposed of a total of 2,065 shares trimming its holdings by 93.3%. The value in dollars decreased from $1,000 to $0 decreasing 100.0% since the last quarter. Tpg Group Holdings (sbs) Advisors, Inc. downsized its position by shedding 3,713,416 shares a decrease of 93.3% from 03/31/2017 to 06/30/2017. Tpg Group Holdings (sbs) Advisors, Inc. owns 265,244 shares with a value of $843,000. The value of the position overall is down by 60.0%.
On September 26 HC Wainwright held the stock rating at “Buy” targeting a price of $15.00. On August 17 analysts at Cowen and Company updated guidance on AMRS with a rating of “Hold” and establishing a price target of $4.00.
On August 11, 2017 HC Wainwright released guidance on AMRS and giving a rating of “Buy” and a price target of $15.00.
The company is so far trading down from yesterday’s close of 3.03. The most current P/E ratio is N/A and market cap is 112.26M. As of the latest earnings report the EPS was $-6.24 with 37.61M shares currently outstanding.
Amyris, Inc., launched on April 15, 2010, is an integrated industrial biotechnology company. The Company is involved in research and development and sales of fuels and farnesene-derived products. The Company is applying its industrial synthetic biology platform to engineer, manufacture and sell products into a range of consumer and industrial markets, including cosmetics, flavors and fragrances (F&F), solvents and cleaners, polymers, lubricants, healthcare products and fuels. The Company intends to apply its technology to the development of pharmaceutical products. The Company focuses on a renewable hydrocarbon molecule called farnesene (Biofene), which forms the basis for a range of products, including emollients, flavors and fragrance oils and diesel fuel. The Business’s subsidiaries are Amyris Brasil Ltda. and Amyris Fuels, LLC..